©2025 Bryn Mawr Communications, LLC.
All Rights Reserved

Terms and Conditions • Privacy Policy

Meeting Coverage:

EURETINA Congress

EURETINA: 2024

Anti-VEGF for ROP: Efficacy and Safety Outcomes

Andreas Stahl, MD

Show Description +

Dr. Stahl summarizes the 3-year efficacy and safety data from the FIREFLEYE Next study of children with retinopathy of prematurity treated with intravitreal aflibercept versus laser.

Posted: 10/03/2024

Keywords:

retina-meeting-recap

•

Clinical Trials

•

Safety

•

firefleye

•

Retinopathy of prematurity, ROP,

•

Intravitreal Injection

•

Intravitreal Therapy

•

aflibercept

•

laser

•

Eylea

•

Regeneron Pharmaceuticals

Up Next

Advancing Research Methodology in Retina
Advancing Research Methodology in Retina

Varun Chaudhary, MD, FRCS(C)

The Clinical Challenges of AAV Vectors
The Clinical Challenges of AAV Vectors

Kanmin Xue, PhD, MA, MB, BChir, FRCOphth

Plasma Kallikrein Inhibition: A Novel Approach to DME
Plasma Kallikrein Inhibition: A Novel Approach to DME

Arshad Khanani, MD, MA, FASRS

Next-Gen Therapies for AMD and DME
Next-Gen Therapies for AMD and DME

Nicole Eter, MD

The Role of Anti-VEGF Therapy in Diabetic Vitreous Hemorrhage
The Role of Anti-VEGF Therapy in Diabetic Vitreous Hemorrhage

David Steel, MD, MBBS, FRCOphth

Exploring VEGF-C and -D Inhibition
Exploring VEGF-C and -D Inhibition

Timothy L. Jackson, PhD, MB ChB, FRCOphth

The Clinical Benefits of the PDS
The Clinical Benefits of the PDS

Patricia Udaondo, MD

RD Repair: Why Slower Reattachment is Better
RD Repair: Why Slower Reattachment is Better

Stratos V. Gotzaridis, MBBS, MD

Today's Approaches to Myopic Neovascularization
Today's Approaches to Myopic Neovascularization

Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI

link-arrow   Back to All Videos

Anti-VEGF for ROP: Efficacy and Safety Outcomes

Andreas Stahl, MD

Dr. Stahl summarizes the 3-year efficacy and safety data from the FIREFLEYE Next study of children with retinopathy of prematurity treated with intravitreal aflibercept versus laser.

Posted: 10/03/2024

Keywords:

retina-meeting-recap

•

Clinical Trials

•

Safety

•

firefleye

•

Retinopathy of prematurity, ROP,

•

Intravitreal Injection

•

Intravitreal Therapy

•

aflibercept

•

laser

•

Eylea

•

Regeneron Pharmaceuticals

Please log in to leave a comment.

More From EURETINA: 2024 Coverage

The Clinical Benefits of the PDS
The Clinical Benefits of the PDS

Patricia Udaondo, MD

RD Repair: Why Slower Reattachment is Better
RD Repair: Why Slower Reattachment is Better

Stratos V. Gotzaridis, MBBS, MD

Today's Approaches to Myopic Neovascularization
Today's Approaches to Myopic Neovascularization

Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI

Advancing Research Methodology in Retina
Advancing Research Methodology in Retina

Varun Chaudhary, MD, FRCS(C)

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of EURETINA: 2024.

close-x